Safety and PK of BW-40202 in Healthy Volunteers

Phase 1, randomised, double-blind trial of BW-40202 in paroxysmal nocturnal hemoglobinuria (PNH) and IgA nephropathy (IgAN) (6 arms), sponsored by Shanghai Argo Biopharmaceutical Co., Ltd. Primary endpoints: Proportion of participants experiencing at least one treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) at Day 169, Adverse events categorized by MedDRA terms at Day 169 and 8 more. Started Jun 2025; status: recruiting.